GlassScriptPhysician profile
Bryan D Quinn
NPI 1689887911
$5,098.70
in general payments reported to CMS, 2019-2025
31 companies · $831 in 2025
The $831 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $821 · 2020: $460 · 2021: $645 · 2022: $585 · 2023: $922 · 2024: $835 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,329 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,328.58 |
| Education | $259.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $744.82 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $532.95 | 2019-2025 | Tavneos, Krystexxa, Aranesp |
| Opko Pharmaceuticals, LLC | $491.29 | 2019-2024 | Rayaldee |
| Akebia Therapeutics INC | $464.16 | 2019-2024 | Auryxia, Vafseo |
| Otsuka America Pharmaceutical, INC. | $382.34 | 2019-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $360.64 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Aurinia Pharma U.S., INC. | $251.89 | 2023-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $241.34 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $194.50 | 2023-2025 | |
| Travere Therapeutics, INC. | $179.92 | 2019-2025 | Filspari |
| Horizon Therapeutics Plc | $168.98 | 2019-2023 | Krystexxa |
| Vifor Pharma, INC. | $163.78 | 2019-2024 | Veltassa, Korsuva |
| Ardelyx, INC. | $130.22 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $100.77 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $81.49 | 2020-2025 | Acthar |
| Glaxosmithkline, LLC. | $78.31 | 2021-2024 | Benlysta |
| Lilly USA, LLC | $53.56 | 2024 | Jardiance |
| Apellis Pharmaceuticals, INC. | $44.59 | 2025 | Empaveli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.76 | 2022-2023 | Jardiance |
| Calliditas Therapeutics US INC. | $42.24 | 2022-2025 | Tarpeyo |
| Genzyme Corporation | $39.70 | 2023 | |
| Vantive US Healthcare LLC | $30.89 | 2025 | Renal - Crrt |
| Ultragenyx Pharmaceutical INC. | $23.06 | 2021 | |
| One Lambda, INC. | $21.99 | 2025 | |
| Alexion Pharmaceuticals, INC. | $21.74 | 2019 | |
| Scpharmaceuticals INC. | $18.74 | 2025 | |
| Cook Medical LLC | $18.11 | 2022 | |
| Nxstage Medical, INC. | $16.88 | 2019 | |
| Shire North American Group INC | $16.19 | 2019 | |
| Novo Nordisk INC | $14.85 | 2025 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Quinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.